Latest California Healthline Stories
An annual government survey of drug use and health shows a dramatic drop in the number of people who tried heroin but an uptick in pot use.
In this episode of KHN’s “What the Health?” Sarah Jane Tribble of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Kimberly Leonard of the Washington Examiner and Rebecca Adams of CQ Roll Call talk about the Food and Drug Administration’s latest actions to address teenagers’ use of e-cigarettes, Arkansas’ Medicaid work requirements and news about the uninsured from the latest federal Census report.
The Golden State, with the rare support of the Trump administration, is seeking to circumvent a court order that would require cancer warnings in every establishment that sells a hot cup of Joe.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico discuss Senate action on health funding and opioid legislation, the state of the individual insurance market and consternation over expiration dates on EpiPens, the self-injected allergy remedy. Also, could an otter with asthma signal a potential public health crisis?
Critics worry about the message federal officials are sending by approving a new birth control option, which uses a mobile phone app for women to track their body temperature and menstrual cycle to avoid pregnancy. But the more choices the better, some reproductive health experts say.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Alice Ollstein of Talking Points Memo and Kimberly Leonard of the Washington Examiner talk about the new push on health legislation by Republicans in the House, as well as developments on Medicaid work requirements, drug prices and the fate of children separated from their parents at the U.S.-Mexican border. Plus, for extra credit, the panelists offer their favorite health stories of the week.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
Vaping is becoming increasingly popular in the United States, especially among young people. This fact is triggering an unexpected divide within the public health community and complicating efforts to regulate the industry.
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.